Source comparison
CJC-1295 No DAC & Ipamorelin vs Other Research Peptides: Comparison
The following table compares CJC-1295 No DAC with ipamorelin against other common research peptides across critical parameters that determine protocol suitability. CJC-1295 No DAC + Ipamorelin 200–400% (pulsatile) 6–8 days (CJC) / 2 hours (Ipa) None Minimal Tw
This comparison does not assign a generated winner or score.
- The following table compares CJC-1295 No DAC with ipamorelin against other common research peptides across critical parameters that determine protocol suitability.
- CJC-1295 No DAC + Ipamorelin
- 200–400% (pulsatile)
- 6–8 days (CJC) / 2 hours (Ipa)
- None
- Minimal
- Twice daily (Ipa) + twice weekly (CJC)
- Gold standard for long-duration metabolic studies. Sustained pulsatile GH without hormonal side effects or receptor downregulation
- GHRP-2
- 250–500% (pulsatile)
- <30 minutes
- +35% cortisol, +28% prolactin
- Low
- Three times daily
- Effective GH elevation but cortisol/prolactin confounds make it unsuitable for clean metabolic or recovery endpoints
- GHRP-6
- 300–600% (pulsatile)
- +20% cortisol, moderate prolactin
- Strong GH response with appetite stimulation (ghrelin effect). Useful in studies targeting caloric surplus but confounds fat loss protocols
- Hexarelin
- 600–900% (acute spike)
- <60 minutes
- Moderate cortisol elevation
- Very high (40–60% drop by day 14)
- Once daily (short-term only)
- Highest acute GH spike but rapid desensitisation limits use to 10–14 day protocols. Not viable for long-term studies
- MK-677 (Ibutamoren)
- 150–300% (continuous)
- 24 hours
- Moderate (endogenous suppression over time)
- Once daily (oral)
- Convenient oral dosing but continuous GH elevation risks insulin resistance and blunts natural pulsatility. Best for convenience-prioritized studies
- Sermorelin
- 150–250% (pulsatile)
- <10 minutes
- Two to three times daily
- Short half-life requires frequent dosing; lower GH amplitude than ipamorelin but no off-target effects